Nuvectis Pharma Inc — Cash Flow (NASDAQ:NVCT) | MetaTrader

Open full chart

Financials

Overview Estratto Conto Statistics Dividends

Quarterly Annual

Cash from operating activities 13.56 M15.95 M12.25 M16.01 M 16.01 M Cash from investing activities —000 0 Cash from financing activities 27.81 M15.09 M11.65 M29.11 M 29.11 M Free cash flow 13.56 M15.95 M12.25 M16.01 M 16.01 M

Notizie

Nuvectis initiates phase 1b trial combining NXP900 with osimertinib

H.C. Wainwright重申Nuvectis Pharma股票评级为"买入"

Nuvectis Pharma stock rating reiterated at Buy by H.C. Wainwright

卡普兰以64,240美元购入Nuvectis Pharma (NVCT)股票

Nuvectis Pharma董事长Bentsur购入价值28,600美元的股份

Nuvectis Pharma董事Sanchez以7.5万美元购入NVCT股票

H.C. Wainwright维持Nuvectis Pharma股票买入评级，目标价10美元

H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target

Nuvectis Pharma adds former Intra-Cellular exec to board of directors

Nuvectis initiates phase 1b program for cancer drug NXP900

Nuvectis (NVCT) Q2 Loss Widens 43%

Nuvectis Pharma stock price target lowered to $10 at H.C. Wainwright